Up-regulated p-ERK1/2 was also observed in the SCLC cell line NCI-H510 (Fig. 4b), suggesting that synergy results from these cell lines becoming more dependent on MEK/ERK signaling as a result of adaptive pathway activation following GSK525762 treatment. The gene discussed is MAPK3; the disease is small cell lung carcinoma.